On 28 November 2024, Celltrion announced the commencement of global phase 3 clinical trials for CT-P44, biosimilar to Janssen’s Darzalex® (daratumumab), following submission of its global phase 3 clinical trial plan (IND) to the European Medicines Agency (EMA).
Earlier this month, Celltrion announced record high sales for Q3 2024, reaching KRW 2.4 trillion, up 31.2% year on year. Celltrion also revealed this month the preclinical study results of two new antibody-drug conjugate (ADC) candidates – with Celltrion internal codes CT-P70 and CT-P71, designed to target solid cancers.